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Introduction {#sec1}
============

Osteoporosis is the most common metabolic bone disease, and it affects many people such as the elderly, long-term bed-ridden patients, astronauts, and persons living sedentary lifestyles ([@bib2], [@bib7], [@bib18], [@bib29]). Disuse or unloading-induced osteoporosis leads to an insufficient number of osteoblasts or a reduction in their function. These effects are well known as some of the main causes in the pathogenesis of osteoporosis ([@bib16], [@bib24]). Therefore, drugs that induce the differentiation and proliferation of osteoblasts, thus promoting bone formation, may represent a strategy for the prevention and treatment of osteoporosis, which, however, still remains an unmet medical need.

Recent reports showed that glucagon-like peptide-1 (GLP-1), a gastrointestinal hormone whose release is stimulated by ingestion, acts as an important modulator of bone growth and remodeling ([@bib15], [@bib36]). In addition, our previous investigation suggested that exendin-4 (Ex-4), a peptide analog of GLP-1, induced bone formation by osteoblast activation in old ovariectomized (OVX) rats ([@bib22]), raising a new question regarding the downstream molecular mechanisms underlying the osteogenic effect. The elucidation of this effect would provide insight into the pathophysiology of osteoporosis and the pharmacological properties of GLP-1 and its analogs.

GLP-1 and its analogs exert their physiological and pharmacological effects mainly via the GLP-1 receptor (GLP-1R). However, at present GLP-1R expression in osteoblasts has not been clearly confirmed. Many studies reported that GLP-1R was not expressed in primary osteoblasts and Saos-2 cells ([@bib1], [@bib3], [@bib36]). Other research reported that GLP-1R was expressed in young osteoblasts derived from TE-85 and MG-63, but not in mature osteoblasts derived from Saos-2 osteosarcoma cell line ([@bib26]). At the same time, GLP-1R was also detected during osteogenic differentiation of human adipose-derived stem cells ([@bib12]). In our previous work, we found that Ex-4 osteogenic action in OVX rats was a consequence of the differentiation of bone marrow stromal cells (BMSCs) through the promotion of osteogenesis and a simultaneous suppression of adipogenesis ([@bib22]). Moreover, additional experimental analyses demonstrate the presence of the GLP-1R mRNA and protein in human BMSCs ([@bib30]). These lines of evidence provide a strong hint that BMSCs might be a cell target that mediates the osteogenic effect of GLP-1 and its analogs.

BMSCs are potential stem cells with the ability to differentiate into osteoblasts or adipocytes depending on the situation ([@bib28]). Indeed, several molecules possess a role in regulating the differentiation of BMSCs ([@bib5], [@bib31], [@bib37]). The Wnt/β-catenin signaling pathway appears to be of particular importance, since its activation promotes BMSCs differentiation into osteoblast cells while suppressing their adipogenic potential ([@bib20]), which is highly similar to the effect of GLP-1 and its analogs. In particular, β-catenin stabilization and induction of its translocation into the nucleus play an important role in promoting BMSC osteogenic differentiation. Furthermore, previous studies suggested that β-catenin may have interactive effects on the cyclic AMP (cAMP) signaling pathway ([@bib10], [@bib14]). The enhancement of cAMP signaling was reported to facilitate β-catenin signaling in many types of cells ([@bib13], [@bib19], [@bib38]). Therefore, since GLP-1Rs are G-protein-coupled receptors able to induce intracellular cAMP formation and trigger the cAMP-protein kinase A (PKA) signaling pathway when activated ([@bib9], [@bib11]), we hypothesized that Ex-4 might exert its osteoblast activation effect by inducing cAMP and β-catenin signaling in BMSCs.

To prove our hypothesis, we investigated the effect of Ex-4 on BMSC differentiation and bone formation both in vitro and in vivo. With the induction of disuse osteoporosis in tail-suspended rats, our results showed that GLP-1R activation improved osteoporosis and promoted BMSC osteogenic potential through the regulation of the PKA/β-catenin signaling pathway. These results advocate GLP-1 and its analogs as rather promising drugs against osteoporosis.

Results {#sec2}
=======

GLP-1R Agonist Ex-4 Increased Bone Mass and Bone Strength in Hindlimb-Unloading-Induced Bone Loss Rats {#sec2.1}
------------------------------------------------------------------------------------------------------

To elucidate the role of GLP-1R in the control of skeletal homeostasis, we analyzed the bone structural characteristics after GLP-1R agonist Ex-4 treatment in hindlimb-unloading rats. After mechanical unloading for 4 weeks, hindlimb-unloading rats exhibited a lower bone mineral density (BMD) and fewer, thinner, and more broken trabecular bones in femur and vertebra compared with the rats in the normal control group not subjected to hindlimb unloading as well as any other treatment, as displayed by the microcomputed tomography (microCT) scans of femur and vertebra. However, the trabecular architecture was remarkably improved in the Ex-4-treated rats belonging to the hindlimb-unloading treatment group compared with the rats in the hindlimb-unloading control group treated with the vehicle. The BMD and bone volume to tissue volume ratio in the rats of the hindlimb-unloading treatment group were remarkably higher than those in the rats of the hindlimb-unloading control group ([Figures 1](#fig1){ref-type="fig"}A--1C). The trabecular number, trabecular thickness, trabecular spacing, and structure model index were also remarkably improved in the rats of the hindlimb-unloading treatment group ([Figures 1](#fig1){ref-type="fig"}D--1G).

Consistently, the results of the three-point bending test in the femur samples and compression analysis in the vertebra samples showed that the biomechanical properties such as maximum load, stiffness, stress, and Young\'s modulus were decreased after mechanical unloading in the rats of the hindlimb-unloading control group. All parameters were significantly enhanced after Ex-4 treatment ([Figures 1](#fig1){ref-type="fig"}H--1K). Thus, Ex-4 administration can prevent the bone loss and architectural deterioration caused by mechanical unloading in rats.

Ex-4 Stimulated Bone Formation and Increased the Number of Osteoblasts {#sec2.2}
----------------------------------------------------------------------

To further assess how Ex-4 ameliorated the unloading-induced bone loss, we examined the bone formation-related parameters by bone histomorphometry analysis. In agreement with the imaging studies, dynamic histomorphometric analysis of the femoral bone sections from the hindlimb-unloading control group revealed a significant decrease in the bone mineral apposition rate (MAR), bone mineralizing surface when expressed per bone surface (MS/BS), and bone formation rate per bone surface (BFR/BS), determined by double calcein labeling, compared with the normal control group. However, MAR, BFR/BS, and MS/BS were significantly increased after Ex-4 treatment ([Figures 2](#fig2){ref-type="fig"}A--2D). In addition, osteocalcin, bone alkaline phosphatase, and N-terminal propeptide concentrations, biomarkers of bone formation in serum, were significantly reduced in the rats of the hindlimb-unloading control group compared with the normal control rats. The concentrations of the above biomarkers were significantly increased in the rats of the hindlimb-unloading treatment group compared with the hindlimb-unloading control group ([Figures 2](#fig2){ref-type="fig"}E--2G). Moreover, consistent with the reduction of bone formation markers, the number of osteoblasts, as well as the dynamic measures of bone formation, was reduced in the trabecular bone of the hindlimb-unloading control group, while Ex-4 remarkably increased the number of osteoblasts ([Figures 2](#fig2){ref-type="fig"}H and 2I). Interestingly, we also found that the number of adipocytes in the bone marrow of the hindlimb-unloading control group was increased compared with the normal control rats, while this number was dramatically decreased after Ex-4 treatment compared with the hindlimb-unloading control group ([Figures 2](#fig2){ref-type="fig"}J and 2K).

Ex-4 Promoted Osteoblasts and Suppressed BMSC Adipocyte Differentiation {#sec2.3}
-----------------------------------------------------------------------

Although our study indicated that Ex-4 exhibited a bone anabolic effect, there are no reports attesting the presence of GLP-1Rs in osteoblasts. Thus, GLP-1 cannot exert a direct effect on osteoblast differentiation. In addition, since GLP-1R is expressed in human BMSCs, in our attempt to investigate the mechanisms underlying GLP-1R-mediated bone anabolic effect we evaluated whether rat BMSCs expressed GLP-1R using real-time PCR, western blotting, and immunocytochemistry. Our results showed that GLP-1R was not expressed in primary osteoblasts cultured in osteogenesis induction medium (OIM) for 4 weeks, but was expressed in both rat insulinoma cell line (INS-1, GLP-1R-positive cell) and rat BMSCs ([Figures 2](#fig2){ref-type="fig"}L--2N). To evaluate the potential of BMSCs to differentiate into mature matrix-producing osteoblasts after Ex-4 treatment, we cultured BMSCs in OIM or in adipogenesis induction medium (AIM). Our results showed that Ex-4 significantly increased the expression of osteoblast differentiation-related genes and proteins, such as *Runx2*/RUNX2 at day 7 after Ex-4 treatment, *Sp7*/osterix at day 10 ([Figures 3](#fig3){ref-type="fig"}A, 3B, 3D, and 3E), and impaired mineral deposition of cells at day 28 ([Figures 3](#fig3){ref-type="fig"}J and 3L). Ex-4 also increased the expression of mature matrix-producing osteoblast marker genes such as *Balp* and *Bglap* by real-time PCR at day 14 or day 28 after Ex-4 treatment, respectively ([Figures 3](#fig3){ref-type="fig"}G and 3H). In contrast, Ex-4 led to decreases in the mRNA and protein expression of the peroxisome proliferator-activated receptor γ (PPARγ) at day 3 ([Figures 3](#fig3){ref-type="fig"}C and 3F), as well as decreases in the lipoprotein lipase mRNA (*Lpl*) expression at day 14, and consequent lipid production in the differentiated adipocytes, as shown by oil red O at day 21 ([Figures 3](#fig3){ref-type="fig"}I, 3K, and 3M). These data suggested that Ex-4 played an important role in stimulating BMSCs osteoblast differentiation and inhibiting their differentiation into adipocytes. Furthermore, the GLP-1R antagonist exendin(9--39) \[Ex(9--39)\] attenuated the Ex-4 effect of improving osteogenesis and inhibiting adipogenesis of BMSCs ([Figures 3](#fig3){ref-type="fig"}A--3M), indicating that GLP-1R might play an important role in regulating BMSC differentiation. To further determine whether Ex-4 mediated BMSC differentiation through the activation of GLP-1Rs, we downregulated BMSC GLP-1R via lentiviral small hairpin RNA (shRNA) infection, and the cells were subsequently treated with 10 nM Ex-4. Our results showed that the effect of Ex-4 on enhancing the expression of *Runx2*, *Pparγ*, *Balp*, and *lpl* was abolished when BMSCs were infected with shRNA15015, shRNA15016, or shRNA15017 ([Figure S1](#mmc1){ref-type="supplementary-material"}). Moreover, GLP-1R downregulation by shRNA15016 reduced the effect of Ex-4 on the promotion of genes and protein expression related to osteoblast differentiation, and abolished Ex-4-promoted mineralization of differentiated osteoblasts. In contrast, the inhibitory effects of Ex-4 on adipocyte differentiation were reversed by GLP-1R downregulation ([Figures 3](#fig3){ref-type="fig"}A--3M). These data indicated that GLP-1R receptor was involved in BMSC osteoblast differentiation while it inhibited their differentiation into adipocytes.

Ex-4 Effect on β-Catenin in BMSCs {#sec2.4}
---------------------------------

Since the canonical Wnt/β-catenin signaling pathway plays a pivotal role in the modulation of BMSC differentiation, we investigated whether it was involved in the effect of Ex-4 on BMSC differentiation through GLP-1R. Our western blot results showed that Ex-4 treatment increased the accumulation of β-catenin in the cytoplasm and enhanced the translocation of β-catenin in the nucleus in a time-dependent manner ([Figures 4](#fig4){ref-type="fig"}A--4C). These data were confirmed by immunofluorescence staining ([Figure S2](#mmc1){ref-type="supplementary-material"}). Since the stable cytosolic β-catenin possesses the ability to transfer into the nucleus and bind with the transcription factor 7-like 2 (TCF7L2) to activate the expression of Wnt signaling target genes, including osteogenic regulatory genes, we evaluated the *TCF7L2* mRNA expression level. Ex-4 upregulated *TCF7L2* mRNA expression compared with control ([Figure 4](#fig4){ref-type="fig"}D). The block or downregulation of GLP-1R by Ex(9--39) or shRNA, respectively, inhibited the induction of *TCF7L2* induced by Ex-4 ([Figure 4](#fig4){ref-type="fig"}D). In addition, the levels of the osteogenic regulators Runx2 and osterix were increased by Ex-4, but were decreased when BMSCs were pretreated with Ex(9--39) or shRNA-GLP-1R ([Figures 3](#fig3){ref-type="fig"}D and 3E). These results suggested that GLP-1R induced β-catenin nuclear translocation, and improved the expression of TCF7L2 and osteogenic regulators.

Ex-4 Stimulated β-Catenin Nuclear Translocation through PKA/β-Catenin and PKA/PI3K/AKT/GSK3β Signaling Pathways {#sec2.5}
---------------------------------------------------------------------------------------------------------------

To further elucidate how GLP-1R interacted with the canonical Wnt/β-catenin signaling pathway, we investigated the downstream effectors used by GLP-1R and the Wnt/β-catenin system in BMSCs. Our results showed that the activation of GLP-1R by Ex-4 significantly enhanced the level of the PKA catalytic subunit (PKAc), which is associated with the increased phosphorylation of Ser-675 in the cytosolic β-catenin and accumulation of β-catenin in the nucleus. Forskolin treatment potentiated the PAKc and β-catenin level, either in the cytoplasm or in the nucleus, evoked by Ex-4 ([Figures 5](#fig5){ref-type="fig"}A--5D). Moreover, Ex-4-stimulated Ser675 phosphorylation and β-catenin nuclear accumulation were inhibited by either the GLP-1R antagonist Ex(9--39), the PKA inhibitor H89, or the shRNA-GLP-1R ([Figures 5](#fig5){ref-type="fig"}A--5D). Furthermore, the co-immunoprecipitation assay revealed that Ex-4 promoted the physical interaction between PKA and β-catenin ([Figure 5](#fig5){ref-type="fig"}E). We further explored the direct interaction between GLP-1R/PKA signaling and the phosphoinositide 3-kinase (PI3K)/AKT/β-catenin signaling pathway. Our results showed that the increase in PKAc induced by Ex-4 was associated with the phosphorylation of PI3K and its downstream target AKT, as well as with a decrease of phospho-glycogen synthase kinase 3β (p-GSK3β) (Ser9) and an increase of β-catenin accumulation in the cytoplasm and nucleus ([Figures 5](#fig5){ref-type="fig"}F--5L). Treatment with wortmannin, a PI3K inhibitor, inhibited the Ex-4-induced increases of pPI3K and p-AKT, increased the level of p-GSK3β, and abrogated the cytoplasmic and nuclear accumulation of β-catenin ([Figures 5](#fig5){ref-type="fig"}F and 5H--5L). However, wortmannin did not significantly suppress PKAc ([Figure 5](#fig5){ref-type="fig"}G). We next verified the association between PKA and PI3K through a co-immunoprecipitation assay in BMSCs using anti-PKA phosphosubstrate antibody followed by immunoblotting for PI3K. As shown in [Figure 5](#fig5){ref-type="fig"}M, PKA decreased PI3K in Ex-4-treated cells, indicating that Ex-4 facilitated the physical interaction between PKA and PI3K. In addition, Wnt3a, a prototypic Wnt ligand of the frizzled receptor, only increased the nuclear accumulation of β-catenin, but did not affect PKAc in BMSCs compared with the effects of Ex-4 on the induction of PKA and β-catenin. Moreover, Ex-4 stimulation of β-catenin nuclear accumulation was potentiated by the addition of Wnt3a ([Figures 5](#fig5){ref-type="fig"}N--5P). In contrast, Dickkopf 1 (DKK1), a Wnt signaling pathway inhibitor, did not inhibit the accumulation of β-catenin in the nucleus evoked by Ex-4 ([Figures 5](#fig5){ref-type="fig"}N and 5P). The knockdown of β-catenin by shRNA in BMSCs abolished Ex-4 stimulation of β-catenin accumulation in the nucleus of BMSCs, but did not affect Ex-4-induced PKA induction ([Figures 5](#fig5){ref-type="fig"}N--5P).

β-Catenin Regulated BMSC Differentiation through GLP-1R {#sec2.6}
-------------------------------------------------------

To further confirm the key role of β-catenin in the modulating effect of GLP-1R on BMSC differentiation, we also explored the effect of silencing β-catenin in BMSCs. Our results showed that the effect of Ex-4 on *Runx2*, *Pparγ*, *Balp*, and *lpl* expression was abolished when BMSCs were infected with shRNA19538 and shRNA19539, but not with shRNA19537 ([Figure S3](#mmc1){ref-type="supplementary-material"}). Moreover, shRNA19538-mediated downregulation of β-catenin in BMSCs inhibited the expression of osteoblast differentiation and maturation markers such as *Runx2*/RUNX2, *Sp7*/osterix, *Balp*, and *Bglap*, and significantly reduced the mineralization evoked by Ex-4 ([Figures 6](#fig6){ref-type="fig"}A, 6B, 6D, 6E, 6G, 6H, 6J, and 6L). On the other hand, the inhibition of the adipocyte differentiation and lipid production in BMSCs mediated by Ex-4 was reversed by β-catenin downregulation ([Figures 6](#fig6){ref-type="fig"}C, 6F, 6I, 6K, and 6M). All the Ex-4-induced functions on BMSCs, such as induction of the markers related to osteoblast differentiation, BMSC mineralization, and the repression of the markers related to adipocyte differentiation, were not affected by DKK1 treatment ([Figure 6](#fig6){ref-type="fig"}), suggesting that DKK1 did not affect Ex-4-mediated increase of nuclear β-catenin via the GLP-1R/PKA pathway.

Discussion {#sec3}
==========

The present study analyzed and described the link between GLP-1R and the Wnt/β-catenin signaling pathway in BMSCs, in which GLP-1R receptor crosstalks with the canonical Wnt/β-catenin pathway to promote bone formation. Our results demonstrated that GLP-1R, mainly expressed on BMSCs, promoted BMSC osteoblast differentiation and inhibited their differentiation into adipocytes, leading to the anabolic bone formation and amelioration of osteoporosis in hindlimb-unloading rats. The mechanisms of GLP-1R-mediated osteogenic action is exerted by a dual role: through the cAMP/PKA/β-catenin/T cell factor (TCF) pathway to initiate osteoblast differentiation, and through the PKA/PI3K/Akt/GSK3β pathway to inhibit β-catenin degradation and promote its nuclear accumulation in BMSCs, which thereafter resulted in the anabolic bone formation.

The gut-derived hormones, such as serotonin, peptide YY (PYY), and incretins, are now recognized as critical regulators in bone homeostasis ([@bib6], [@bib34], [@bib35]), since they display a negative relationship with osteoblast activity. Therefore, these results provide evidence that the inhibition of the biosynthesis of gut-derived serotonin and PYY could become an effective method to treat low-bone-mass diseases such as osteoporosis.

In contrast to the negative regulation of serotonin and PYY on bone homeostasis, our study demonstrated that GLP-1R displayed a positive correlation with osteoblast activity and bone growth. The treatment with the GLP-1R agonist Ex-4 resulted in a significant increase in bone mass in the hindlimb-unloading rats, associated with the increase in osteoblast number and serum level of bone formation biomarkers, with a parallel decrease in the adipocyte number. In addition, the treatment with Ex-4 lowered the increased rates of bone resorption biomarkers ([Figure S4](#mmc1){ref-type="supplementary-material"}). These findings strongly indicated that Ex-4 prevented osteopenia by promoting bone formation and suppressing bone resorption. The effect of Ex-4 in the control of bone resorption is exerted through a calcitonin-dependent pathway ([@bib36]). However, GLP-1Rs are not present in osteoblasts, so GLP-1 cannot exert a direct effect on them ([@bib3], [@bib36]). Therefore, the anabolic effects of Ex-4 on bone formation that we observed were not a consequence of a direct action on osteoblasts. As it is well known that osteoblasts and adipocytes both differentiate from common mesenchymal precursor cells ([@bib27]), we speculated that the changes in the osteoblast and adipocyte numbers might be due to BMSC differentiation preferably to adipocytes rather than osteoblasts, leading to bone formation reduction and consequent osteopenia development, while GLP-1R is expressed in human BMSCs to promote cellular proliferation and prevent the differentiation of human MSCs into adipocytes ([@bib30]). Thus, we hypothesized that BMSC GLP-1R might play a regulatory role in cell fate, resulting in osteoblast differentiation rather than adipocyte differentiation. To test this hypothesis, we investigated the roles of GLP-1R on BMSC differentiation. BMSC GLP-1R activation by Ex-4 significantly enhanced the expression of osteoblastogenic biomarkers, thus promoting osteoblastic mineralization, and inhibited the induction of adipocyte differentiation biomarkers, thus decreasing endogenous lipoid deposits in cells. GLP-1R silencing or block through its antagonists reduced the effects described above. Taken together, these results suggested that GLP-1R is involved in BMSC differentiation into osteoblasts.

Recent studies indicate that the canonical Wnt pathway affects BMSC osteogenic differentiation. Wnt signaling can promote osteoblastic precursor differentiation into more differentiated osteoblasts and can serve as a negative regulator of adipogenesis ([@bib8], [@bib17]). This differentiation process is tightly regulated by complex signaling events ([@bib21]). β-Catenin is indeed a key signaling molecule that promotes cell differentiation. Our results showed that Ex-4 dramatically promoted β-catenin nuclear translocation and TCF7L2 expression in BMSCs. These effects were significantly inhibited by the block or knockdown of GLP-1R, suggesting that GLP-1R was involved in crosstalk with the β-catenin signaling pathway.

GLP-1R is localized in multiple tissues and cell types ([@bib11]). GLP-1 agonist binding to GLP-1R activates various different pathways involved in the proliferation, differentiation, and protection from apoptosis. On the basis of our present results we concluded that PKA, a GLP-1R downstream effector exerting a strong bond to β-catenin and PI3K and induced by Ex-4, played a dual role in its interaction with the Wnt/β-catenin signaling pathway. First, at the molecular level, PKA phosphorylated β-catenin at its Ser675 and promoted β-catenin nuclear translocation, and subsequently recruited LEF/TCF DNA binding factors to initiate the expression of osteoblast differentiation-related gene, driving BMSC differentiation into osteoblasts. It has also been reported that PKA phosphorylates β-catenin at two sites, Ser552 and Ser675, thus preventing its ubiquitination and thereby stabilizing β-catenin ([@bib10], [@bib33]). Second, PKA also phosphorylated PI3K, which in turn phosphorylated AKT, leading to GSK3β phosphorylation. GSK3β is a key enzyme that negatively regulates the canonical Wnt/β-catenin signaling pathway, and canonical Wnt signaling activation also requires the inhibition of GSK3β activity ([@bib4]). The PKA signaling pathway can crosstalk with the PI3K/AKT pathway in endothelial cells ([@bib25]), and the PI3K/AKT pathway can communicate with the GSK3β/β-catenin pathway in epithelial cells ([@bib32]). Phosphorylated GSK3β dephosphorylates β-catenin and prevents its degradation in the ubiquitin-dependent proteosome pathway. This event also helps to promote β-catenin translocation into the nucleus, leading to BMSC osteoblast differentiation. In summary, our results indicated that BMSC GLP-1R plays a crucial role in the regulation of osteoblast differentiation by interacting with the PKA/β-catenin and PKA/PI3K/AKT/GSK3β/β-catenin signaling pathways, both representing critical events in Ex-4-induced anabolic bone formation ([Figure 7](#fig7){ref-type="fig"}).

Experimental Procedures {#sec4}
=======================

Animal Experiments {#sec4.1}
------------------

All experiments and animal care procedures were performed in accordance with the recommendations and guidelines of the NIH and were approved by the Animal Care and Use Committee of the Fourth Military Medical University (Xi\'an, China). The rat tail suspension was performed for 28 days as previously described ([@bib23]). Ex-4 (GL Biochem), 4.2 μg/kg/day, was intraperitoneally administered to the rats of the hindlimb-unloading treatment group for 28 days, while the rats belonging to the hindlimb-unloading control group received an intraperitoneal injection of the same amount of normal saline for the same number of days. The Ex-4 dose used was chosen according to our previous experiment ([@bib22]). Femurs and lumbar vertebrae (L3--L4) were removed and stored at −80°C for microCT analysis and biomechanical testing. The femurs and vertebrae were subjected to a three-point bending test and axial compression analysis using a servo-hydraulic materials testing machine (MTS 858 Mini Bionix II; MTS Systems) to perform a biomechanical analysis. Serum bone formation markers were measured by commercially available ELISA kits. Bone static histomorphometry measurements and bone histology of the trabecular bone were performed as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Cell Experiments {#sec4.2}
----------------

BMSCs were isolated from the femurs and tibias of 2- to 3-week-old Sprague-Dawley male rats (Animal Center of Fourth Military Medical University). The BMSCs derived from the second to the fourth passages were used in all the experiments, at least three different batches per experiment were used, and each experiment was performed in triplicate. BMSC induction was performed using osteogenic or adipogenic induction medium in all experiments. The BMSCs were cultured in OIM containing minimal essential medium α (α-MEM), 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin, 50 mg/l ascorbic acid (Sigma-Aldrich), 10 nM dexamethasone (Sigma-Aldrich), and 10 mM β-glycerophosphate (Sigma-Aldrich) to induce osteogenic differentiation, while they were cultured in AIM containing α-MEM, 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 5 μg/ml insulin (Sigma-Aldrich), 1 μM dexamethasone (Sigma-Aldrich), 0.5 mM 3-isobutyl-1-methylxanthine (Sigma-Aldrich), and 100 μM indomethacin (Sigma-Aldrich) to induce adipogenic differentiation. BMSC GLP-1R and β-catenin were knocked down by lentivirus transduction encoding shRNA. The osteogenic potential was confirmed by mineralization assay and the adipogenic potential was confirmed through oil red O staining. Quantitative real-time PCR, western blot analysis, co-immunoprecipitation, and confocal microscopy detection were also performed (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).

Statistical Analysis {#sec4.3}
--------------------

Data were expressed as mean ± SD and analyzed using SPSS for Windows version 15.0. Statistical significance was determined by one-way ANOVA followed by post hoc multiple comparisons using a Student-Newman-Keuls t test. A value of p \< 0.05 was considered statistically significant.
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![GLP-1R Activation by Ex-4 Increased Bone Mass and Ameliorated Osteoporosis in Hindlimb-Unloading Rats\
(A) MicroCT representative three-dimensional reconstructive images of a trabecular bone from the distal femur metaphyses and L4 vertebrae of normal control rats (Con) and hindlimb-unloaded rats treated with vehicle (H-U) or Ex-4.\
(B--G) MicroCT analysis of distal femur metaphyses and L4 vertebrae from different rat groups (n = 6 independent samples/group). BMD, bone mineral density; BV/TV, bone volume/total volume; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; SMI, structure model index.\
(H--K) Ex-4 improved bone biomechanical properties in femur diaphysis and L3 vertebrae from different rat groups (n = 12 independent samples/group). Maximum load (N) of the bone before crushing; stiffness (N/mm), the slope of the linear region; maximum stress (MPa), the maximum load per cross-sectional area; Young\'s modulus (GPa), maximum slope of the stress-strain curve.\
Bars represent mean and SD. ^∗∗^p \< 0.01 versus normal control rats (Con) and ^\#^p \< 0.05, ^\#\#^p \< 0.01 versus hindlimb-unloaded rats (H-U) by one-way ANOVA followed by a Student-Newman-Keuls t test.](gr1){#fig1}

![GLP-1R Activation by Ex-4 Increased Bone Formation and Osteoblast Number\
(A) Images showing the new bone formation of the femur trabecular bone sections of rats treated with vehicle (H-U) or Ex-4. Scale bar, 10 μm.\
(B--D) Dynamic bone histomorphometric parameters in the femur trabecular bone sections (n = 6 independent samples/group). MAR, mineral apposition rate; MS/BS, mineralizing surface/bone surface; BFR/BS, bone formation rates/bone surface area.\
(E--G) Bone formation markers: osteocalcin (OCN), bone alkaline phosphatase (BALP), and N-terminal propeptide (PINP), in the serum of different rat groups (n = 12 independent samples/group).\
(H and I) H&E-stained osteoblasts (yellow arrows) from rats\' tibial sections (H). The number of osteoblasts (N.Ob) per millimeter of trabecular bone surface (BS) was evaluated (n = 6 independent samples/group) (I). Scale bar, 100 μm.\
(J and K) Toluidine blue-stained adipocytes (red arrows) from rats\' tibial sections (J). The number of adipocytes (N.Adipocyte) per square centimeter was evaluated (n = 6 independent samples/group) (K). Scale bar, 100 μm.\
(L--N) GLP-1R in primary osteoblast, rat INS-1 (GLP-1R positive cell), and BMSCs by RT-PCR (L), western blot (M), and immunofluorescence confocal microscopy (N) with GLP-1R antibody (green fluorescence) and Hoechst (blue fluorescence). Scale bar, 50 μm.\
Bars represent mean and SD. ^∗∗^p \< 0.01 versus normal control rats (Con) and ^\#^p \< 0.05, ^\#\#^p \< 0.01 versus hindlimb-unloaded rats (H-U) by one-way ANOVA followed by a Student-Newman-Keuls t test.](gr2){#fig2}

![GLP-1R Activation Promoted BMSC Osteoblast Differentiation and Suppressed their Differentiation into Adipocytes\
(A--C) Real-time PCR of *Runx2*, *Sp7*, and *Pparγ* mRNA in BMSCs subjected to different treatments. *Runx2* and *Sp7* mRNA expression in BMSCs cultured in OIM were examined at days 7 and 10 after treatment, respectively. *Pparγ* mRNA expression in BMSCs cultured in AIM was examined at day 3 after treatment.\
(D--F) Western blot of RUNX2, osterix, and PPARγ proteins in BMSCs subjected to different treatments. RUNX2 and osterix protein expression in BMSCs cultured in OIM were examined at days 7 and 10 after treatment, respectively. PPARγ protein expression in BMSCs cultured in AIM was examined at day 3 after treatment. Bars represent the protein quantitative data normalized by β-actin.\
(G--I) Real-time PCR of *Balp*, *Bglap*, and *Lpl* mRNA in BMSCs subjected to different treatments. *Balp* and *Bglap* mRNA expression in BMSCs cultured in OIM were examined at days 14 and 28 after treatment, respectively. *Lpl* mRNA expression in BMSCs cultured in AIM was examined at day 14 after treatment.\
(J and L) Mineralized matrix in BMSCs and its quantification. BMSCs were cultured in OIM and were stained with alizarin red S at day 28 after treatment. Scale bar, 3mm.\
(K and M) Lipid content in BMSCs and its quantification. BMSCs were cultured in AIM and were stained with oil red O at day 21 after treatment. Scale bar, 50 μm.\
BMSCs were treated with vehicle (Con), 10 nM Ex-4 alone (Ex-4), or pretreated with 100 nM Ex(9--39) for 1 hr followed by 10 nM Ex-4 treatment (Ex-4+Ex(9--39)); the GLP-1R silenced BMSCs by sh-glp-1r were treated with 10 nM Ex-4 alone (sh-glp-1r + Ex-4) in OIM or AIM. Data are expressed as mean ± SD from three independent experiments. ^∗∗^p \< 0.01 versus vehicle treatment (Con), ^\#^p \< 0.05, ^\#\#^p \< 0.01 versus Ex-4 treatment by one-way ANOVA followed by a Student-Newman-Keuls t test.](gr3){#fig3}

![GLP-1R Activation Induced β-catenin Nuclear Translocation in BMSCs\
(A) Western blot of cytoplasmic (C-β-cat) and nuclear β-catenin (N-β-cat) proteins in BMSCs stimulated by 10 nM Ex-4 at the indicated times.\
(B and C) Bars represent the quantification of the cytoplasmic and nuclear β-catenin protein normalized by β-actin or histone H3.1.\
(D) Real-time PCR of *TCF7L2* mRNA in BMSCs subjected to different treatments. BMSCs were cultured in OIM.\
Data are expressed as mean ± SD from three independent experiments. ^∗∗^p \< 0.01 versus vehicle treatment (Con), ^\#\#^p \< 0.01 versus Ex-4 treatment by one-way ANOVA followed by a Student-Newman-Keuls t test.](gr4){#fig4}

![GLP-1R Activation Stimulated Wnt/β-Catenin Signaling in BMSCs\
(A--D) Western blot of catalytic PKA (PKAc), phosphorylated β-catenin (β-cat Ser675), and nuclear β-catenin (N-β-cat) proteins in BMSCs under different treatments. In (B)--(D) bars represent the quantification of catalytic PKA, β-cat Ser675, and nuclear β-catenin protein normalized by β-actin or histone H3.1.\
(E) Immunoprecipitation and western blot of the interaction between PKA and β-catenin in BMSCs cytoplasm after Ex-4 treatment.\
(F) Western blot of PKAc, phospho-PI3K (p-PI3K), phospho-AKT (p-AKT), phospho-GSK3β (p-GSK3β), C-β-cat, or N-β-cat proteins in BMSCs after treatment with Ex-4 or Ex-4 plus wortmannin (PI3K inhibitor).\
(G--L) Bars represent the quantification of PKAc, p-PI3K, p-AKT, p-GSK3β, C-β-catenin, and N-β-cat proteins normalized by β-actin.\
(M) Immunoprecipitation and western blot of the interaction between PKA and PI3K in BMSC cytoplasm after Ex-4 treatment.\
(N) Western blot of catalytic PKA (PKAc) and nuclear β-catenin (N-β-cat) proteins in BMSCs after different treatments.\
(O and P) Bars represent the quantification of catalytic PKA and nuclear β-catenin protein normalized by β-actin or histone H3.1.\
BMSCs were cultured in OIM. Data are expressed as mean ± SD from three independent experiments. ^∗∗^p \< 0.01 versus vehicle treatment (Con) and ^\#\#^p \< 0.01 versus Ex-4 treatment by one-way ANOVA followed by a Student-Newman-Keuls t test.](gr5){#fig5}

![β-Catenin Silencing Abolished Ex-4 Regulatory Effects on BMSC Differentiation\
(A--C) Real-time PCR of *Runx2*, *Sp7*, and *Pparγ* mRNA in BMSCs subjected to different treatments. *Runx2* and *Sp7* mRNA expression in BMSCs cultured in OIM were examined at days 7 and 10 after treatment, respectively. *Pparγ* mRNA expression in BMSCs cultured in AIM was examined at day 3 after treatment.\
(D--F) Western blot of RUNX2, osterix and PPARγ proteins in BMSCs subjected to different treatments. RUNX2 and osterix protein expression in BMSCs cultured in OIM were examined at days 7 and 10 after treatment, respectively. PPARγ protein expression in BMSCs cultured in AIM was examined at day 3 after treatment. Bars represent the protein quantitative data normalized by β-actin.\
(G--I) Real-time PCR of *Balp*, *Bglap*, and *Lpl* mRNA in BMSCs subjected to different treatments. *Balp* and *Bglap* mRNA expression in BMSCs cultured in OIM were examined at days 14 and 28 after treatment, respectively. *Lpl* mRNA expression in BMSCs cultured in AIM was examined at day 14 after treatment.\
(J and L) Mineralized matrix visualized in BMSCs and its quantification. BMSCs were cultured in OIM and stained with alizarin red S at day 28 after treatment. Scale bar, 3 mm.\
(K and M) Lipid accumulation in BMSCs and its quantification. BMSCs were cultured in AIM and stained with oil red O at day 21 after treatment. Scale bar, 50 μm.\
BMSCs were treated with vehicle (Con), 10 nM Ex-4 alone (Ex-4), 10 nM Ex-4 plus 0.5 mg/ml DKK1 (Ex-4+DKK1); β-catenin silenced BMSCs by sh-β-catenin were treated with 10 nM Ex-4 alone (Ex-4+sh-β-cat) in OIM or AIM. Data are expressed as mean ± SD from three independent experiments. ^∗∗^p \< 0.01 versus vehicle treatment (Con) and ^\#\#^p \< 0.01 versus Ex-4 treatment by one-way ANOVA followed by a Student-Newman-Keuls t test.](gr6){#fig6}

![Model Representing the GLP-1R Role on Promoting BMSCs Osteoblast Differentiation and Suppressing Their Differentiation into Adipocytes through Crosstalk with β-Catenin Signaling Pathway\
GLP-1 agonist, GLP-1, or Ex-4 bound to GLP-1R activates the adenylyl cyclase with a consequent production of cyclic AMP and subsequent activation of PKA. GLP-1-mediated activation of PKA results in β-catenin phosphorylation on Ser675, leading to its nuclear translocation and initiation of the osteogenic gene expression. The activated PKA also phosphorylates PI3K, leading to the activation of AKT. Phosphorylated PKA subsequently phosphorylates GSK3β, resulting in the inhibition of GSK3β activity. β-Catenin degradation mediated by GSK3β is thus inhibited and nuclear accumulation of β-catenin is potentiated. Finally, BMSC osteoblast differentiation takes place and anabolic bone formation is promoted.](gr7){#fig7}
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